Literature DB >> 14517182

Inhibition of interleukin-12 expression by alpha-thrombin in human peripheral blood mononuclear cells: a potential mechanism for modulating Th1/Th2 responses.

A Naldini1, L Aarden, A Pucci, C Bernini, F Carraro.   

Abstract

In addition to its central role in blood coagulation and hemostasis, human alpha-thrombin is a powerful regulator of inflammatory responses and is known to affect cell-mediated immunity. Interleukin (IL)-12 is a strong promoter of the development of Th1-type lymphocytes and its downregulation implies a positive feedback mechanism for development of Th2 responses. We have previously shown that thrombin enhances the release of IL-6, a Th2-related cytokine, in human peripheral blood mononuclear cells (PBMC). Here we show that thrombin downregulates IL-12 production at both protein and mRNA levels in human PBMC. The inhibition of IL-12 production was accompanied by an enhanced release of IL-10, which inhibits Th1-related processes and promotes Th2-type responses. The use of proteolytically inactive thrombin and of the specific thrombin receptor agonist peptide, SFLLRN, reveals that this downregulation is thrombin-specific and requires thrombin proteolytic activity. In addition, activation of coagulation inhibits IL-12 production in whole blood cultures, confirming the tight relationship between the coagulation pathway, where thrombin is a key enzyme, and inflammation. Decreased IL-12 production appears to be related also to IL-10 production, since the addition of an anti-IL-10 monoclonal antibody to thrombin-treated PBMC resulted in a partial restoration of IL-12 production. In conclusion, the observation that thrombin significantly affects the production of IL-12, as well as of IL-10, implies a concerted role orchestrated by thrombin in PBMC that could be crucial to effective immunity and inflammation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14517182      PMCID: PMC1574104          DOI: 10.1038/sj.bjp.0705514

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

Review 1.  The molecular basis of T helper 1 and T helper 2 cell differentiation.

Authors:  A O'Garra; N Arai
Journal:  Trends Cell Biol       Date:  2000-12       Impact factor: 20.808

2.  Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli.

Authors:  M C Minnema; A C Chang; P M Jansen; Y T Lubbers; B M Pratt; B G Whittaker; F B Taylor; C E Hack; B Friedman
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

Review 3.  Protease-activated receptors in inflammation, neuronal signaling and pain.

Authors:  N Vergnolle; J L Wallace; N W Bunnett; M D Hollenberg
Journal:  Trends Pharmacol Sci       Date:  2001-03       Impact factor: 14.819

4.  Th1/Th2 cells, their associated molecules and role in pathophysiology.

Authors:  P Romagnani; F Annunziato; M P Piccinni; E Maggi; S Romagnani
Journal:  Eur Cytokine Netw       Date:  2000-09       Impact factor: 2.737

Review 5.  Acquired antithrombin deficiency in sepsis.

Authors:  B White; D Perry
Journal:  Br J Haematol       Date:  2001-01       Impact factor: 6.998

6.  Thrombin and leukocyte recruitment in endotoxemia.

Authors:  R C Woodman; D Teoh; D Payne; P Kubes
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-09       Impact factor: 4.733

Review 7.  Interleukin-10 and the interleukin-10 receptor.

Authors:  K W Moore; R de Waal Malefyt; R L Coffman; A O'Garra
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

8.  Interleukin 12-activated lymphocytes influence tumor genetic programs.

Authors:  F Cavallo; E Quaglino; L Cifaldi; E Di Carlo; A André; P Bernabei; P Musiani; G Forni; R A Calogero
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

9.  "Normal" thrombin generation.

Authors:  S Butenas; C van't Veer; K G Mann
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

Review 10.  Inflammation-coagulation network: are serine protease receptors the knot?

Authors:  G Cirino; C Napoli; M Bucci; C Cicala
Journal:  Trends Pharmacol Sci       Date:  2000-05       Impact factor: 14.819

View more
  2 in total

1.  Characterization of Early Peripheral Immune Responses in Patients with Sepsis and Septic Shock.

Authors:  Jesús Beltrán-García; Rebeca Osca-Verdegal; Beatriz Jávega; Guadalupe Herrera; José-Enrique O'Connor; Eva García-López; Germán Casabó-Vallés; María Rodriguez-Gimillo; José Ferreres; Nieves Carbonell; Federico V Pallardó; José Luis García-Giménez
Journal:  Biomedicines       Date:  2022-02-23

Review 2.  Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19.

Authors:  Kholoud F Aliter; Rami A Al-Horani
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-01       Impact factor: 3.947

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.